- Oggetto:
- Oggetto:
SOCIAL PROTECTION IN FINANCIALISED AND GLOBALISED CONTEXTS
- Oggetto:
SOCIAL PROTECTION IN FINANCIALISED AND GLOBALISED CONTEXTS
- Oggetto:
Anno accademico 2022/2023
- Codice dell'attività didattica
- CPS0744
- Docente
- Nathalie Yvonne Coutinet Burdin (Titolare dell'insegnamento)
- Corso di studi
- Master's Degree Course in Economic analysis and policy
- Anno
- 2° anno
- Periodo didattico
- Da definire
- Tipologia
- Affine o integrativo
- Crediti/Valenza
- 6
- SSD dell'attività didattica
- SPS/04 - scienza politica
- Modalità di erogazione
- Tradizionale
- Lingua di insegnamento
- Inglese
- Modalità di frequenza
- Obbligatoria
- Tipologia d'esame
- Orale
- Oggetto:
Sommario insegnamento
- Oggetto:
Obiettivi formativi
The objective of this course is to present and analyse:
• the characteristics of the pharmaceutical industry;
• the impact of the financialization of big pharma;
• the history and role of patents on molecules;
• the consequences of TRIPS in terms of access and price;
• the production model of drugs and vaccines;
• the drug policies conducted mainly in Europe.- Oggetto:
Risultati dell'apprendimento attesi
The course provides detailed knowledge on pharmaceutical patents, TRIPS and public health.
- Oggetto:
Modalità di insegnamento
The teaching methods are in the form of lecture courses and flipped classroom.
The courses will be given in English.
- Oggetto:
Modalità di verifica dell'apprendimento
The evaluation will be in the form of a written report.
The expected deadline for the the evaluation is by W19.
- Oggetto:
Programma
Indicative list of lectures:
Lecture 1: Pharmaceutical industry: Key features
Lecture 2: History of patents on drugs
Lecture 3: Trips
Lecture 4: The role of NGOs in access to treatment
Lecture 5: MSF Conference
Lecture 6: The drug production model
Lecture 7: Health care systemTesti consigliati e bibliografia
- Oggetto:
Abecassis et Coutinet, Economie du medicament, Repères, La Découverte,
2018.
Coriat, Orsi et d’Almeida, TRIPS and the international public health
controversies: issues and challenges, Industrial and Corporate Change,
2006.
Jaffe, The U.S. patent system in transition: policy innovation and the
innovation process, Research Policy, 2000.
Abecassis, Coutinet, Coriat, Leyronas, From Product Development
Partnerships to the Commons DNDi Fifteen Years Later,2018, WP9, En
Communs
Wouters, Shadlen, Salcher-Konrad, Pollard, Larson, Teerawattananon, Jit
Challenges in ensuring global access to COVID-19 vaccines: production,
affordability, allocation, and deployment, The Lancet, 2021.- Oggetto:
